Correction: Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial

The numbers in the second paragraph in the section entitled, “Partial primaquine dose and unsupervised primaquine treatment” are incorrect owing to a transcription error in the final preparation of the paper.

The paragraph should read: “For all subsequent recurrences, only the first dose of the antimalarial drugs was supervised. The risk of recurrence after 6 mo of follow-up between the primary and secondary treatments did not differ significantly for patients in either the CQ arm (HR = 1.2 [95% CI 0.8–1.84], p = 0.5) or the AL arm (HR = 0.8 [95% CI 0.5–1.3], p = 0.4). However, patients were at significantly greater risk of recurrent P. vivax after the unsupervised PQ retreatment than after the partially supervised initial PQ treatment: 36.8% (95%CI 16.6%–68.3%) versus 14.7% (95% CI 8.6%–24.6%) in patients in the CQ+PQ arm (HR = 3.9 [95% CI 1.3–11.4], p = 0.014) and 48.1% (95%CI 26.5%–75.6%) versus 17.5% (95%CI 10.7%–27.8%) in patients in the AL+PQ arm (HR = 3.5 [95% CI 1.4–8.9], p = 0.008) (S2 Fig).”